vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and UNIVERSAL DISPLAY CORP \PA\ (OLED). Click either name above to swap in a different company.
UNIVERSAL DISPLAY CORP \PA\ is the larger business by last-quarter revenue ($142.2M vs $123.8M, roughly 1.1× NATURES SUNSHINE PRODUCTS INC). UNIVERSAL DISPLAY CORP \PA\ runs the higher net margin — 25.2% vs 3.3%, a 21.9% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -14.5%). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -5.3%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
NATR vs OLED — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $142.2M |
| Net Profit | $4.1M | $35.9M |
| Gross Margin | 72.5% | 74.6% |
| Operating Margin | 4.3% | 30.1% |
| Net Margin | 3.3% | 25.2% |
| Revenue YoY | 4.7% | -14.5% |
| Net Profit YoY | 1379.4% | -44.3% |
| EPS (diluted) | $0.23 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $142.2M | ||
| Q4 25 | $123.8M | $172.9M | ||
| Q3 25 | $128.3M | $139.6M | ||
| Q2 25 | $114.8M | $171.8M | ||
| Q1 25 | $113.2M | $166.3M | ||
| Q4 24 | $118.2M | $162.3M | ||
| Q3 24 | $114.6M | $161.6M | ||
| Q2 24 | $110.6M | $158.5M |
| Q1 26 | — | $35.9M | ||
| Q4 25 | $4.1M | $66.3M | ||
| Q3 25 | $5.3M | $44.0M | ||
| Q2 25 | $5.3M | $67.3M | ||
| Q1 25 | $4.7M | $64.4M | ||
| Q4 24 | $-321.0K | $46.0M | ||
| Q3 24 | $4.3M | $66.9M | ||
| Q2 24 | $1.3M | $52.3M |
| Q1 26 | — | 74.6% | ||
| Q4 25 | 72.5% | 76.1% | ||
| Q3 25 | 73.3% | 74.6% | ||
| Q2 25 | 71.7% | 77.2% | ||
| Q1 25 | 72.1% | 77.1% | ||
| Q4 24 | 72.0% | 77.0% | ||
| Q3 24 | 71.3% | 77.8% | ||
| Q2 24 | 71.4% | 75.8% |
| Q1 26 | — | 30.1% | ||
| Q4 25 | 4.3% | 38.9% | ||
| Q3 25 | 7.0% | 30.9% | ||
| Q2 25 | 3.7% | 39.9% | ||
| Q1 25 | 5.4% | 41.9% | ||
| Q4 24 | 3.8% | 32.3% | ||
| Q3 24 | 4.6% | 41.5% | ||
| Q2 24 | 5.1% | 35.6% |
| Q1 26 | — | 25.2% | ||
| Q4 25 | 3.3% | 38.4% | ||
| Q3 25 | 4.2% | 31.5% | ||
| Q2 25 | 4.6% | 39.2% | ||
| Q1 25 | 4.2% | 38.8% | ||
| Q4 24 | -0.3% | 28.4% | ||
| Q3 24 | 3.8% | 41.4% | ||
| Q2 24 | 1.2% | 33.0% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $0.23 | $1.40 | ||
| Q3 25 | $0.30 | $0.92 | ||
| Q2 25 | $0.28 | $1.41 | ||
| Q1 25 | $0.25 | $1.35 | ||
| Q4 24 | $-0.02 | $0.96 | ||
| Q3 24 | $0.23 | $1.40 | ||
| Q2 24 | $0.07 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $516.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | — |
| Total Assets | $261.1M | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $516.4M | ||
| Q4 25 | $93.9M | $602.4M | ||
| Q3 25 | $95.6M | $603.0M | ||
| Q2 25 | $81.3M | $525.2M | ||
| Q1 25 | $86.5M | $571.3M | ||
| Q4 24 | $84.7M | $492.7M | ||
| Q3 24 | $78.7M | $551.6M | ||
| Q2 24 | $68.7M | $530.5M |
| Q1 26 | — | — | ||
| Q4 25 | $161.6M | $1.8B | ||
| Q3 25 | $166.7M | $1.7B | ||
| Q2 25 | $163.7M | $1.7B | ||
| Q1 25 | $167.1M | $1.7B | ||
| Q4 24 | $161.0M | $1.6B | ||
| Q3 24 | $162.6M | $1.6B | ||
| Q2 24 | $156.4M | $1.5B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $261.1M | $2.0B | ||
| Q3 25 | $264.8M | $1.9B | ||
| Q2 25 | $254.9M | $1.9B | ||
| Q1 25 | $252.7M | $1.9B | ||
| Q4 24 | $240.9M | $1.8B | ||
| Q3 24 | $245.3M | $1.8B | ||
| Q2 24 | $235.8M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $108.9M |
| Free Cash FlowOCF − Capex | $7.6M | — |
| FCF MarginFCF / Revenue | 6.1% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.41× | 3.03× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $108.9M | ||
| Q4 25 | $9.9M | $31.1M | ||
| Q3 25 | $18.5M | $97.2M | ||
| Q2 25 | $4.3M | $51.9M | ||
| Q1 25 | $2.6M | $30.6M | ||
| Q4 24 | $12.2M | $34.7M | ||
| Q3 24 | $9.6M | $79.9M | ||
| Q2 24 | $1.3M | $67.0M |
| Q1 26 | — | — | ||
| Q4 25 | $7.6M | $15.1M | ||
| Q3 25 | $16.8M | $84.3M | ||
| Q2 25 | $3.0M | $37.5M | ||
| Q1 25 | $1.5M | $17.5M | ||
| Q4 24 | $10.0M | $22.0M | ||
| Q3 24 | $7.9M | $66.2M | ||
| Q2 24 | $-2.0M | $57.9M |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 8.7% | ||
| Q3 25 | 13.1% | 60.4% | ||
| Q2 25 | 2.6% | 21.8% | ||
| Q1 25 | 1.3% | 10.5% | ||
| Q4 24 | 8.5% | 13.6% | ||
| Q3 24 | 6.9% | 41.0% | ||
| Q2 24 | -1.9% | 36.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 9.3% | ||
| Q3 25 | 1.3% | 9.2% | ||
| Q2 25 | 1.2% | 8.4% | ||
| Q1 25 | 1.0% | 7.9% | ||
| Q4 24 | 1.9% | 7.8% | ||
| Q3 24 | 1.5% | 8.4% | ||
| Q2 24 | 3.0% | 5.8% |
| Q1 26 | — | 3.03× | ||
| Q4 25 | 2.41× | 0.47× | ||
| Q3 25 | 3.46× | 2.21× | ||
| Q2 25 | 0.81× | 0.77× | ||
| Q1 25 | 0.55× | 0.47× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | 2.21× | 1.19× | ||
| Q2 24 | 0.97× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
